Here is your PDF: Formaldehyde Fixatives; Keywords: formaldehyde – should methanol solution not 37%

The number of pages within the document is: 3

The self-declared author(s) is/are:
Douglas W. Cromey, M.S.

The subject is as follows:
Original authors did not specify.

The original URL is: LINK

The access date was:
2019-02-04 23:21:58.400470

Please be aware that this may be under copyright restrictions. Please send an email to admin@pharmacoengineering.com for any AI-generated issues.

Loader Loading...
EAD Logo Taking too long?

Reload Reload document
| Open Open in new tab

The content is as follows:
Formaldehyde Fixatives © 2002 – 2012 , The University of Arizona Page 1 Formaldehyde Fixatives Douglas W. Cromey, M.S. – Cellular Imaging Facility Core, Southwest Environmental Health Sciences Center (NIEHS grant # ES 0 06694) Staff – Cell Biology & Anatomy Histology Service Lab, University of Arizona, Tucson, Arizona Informati on about 37% Formaldehyde There is no definitive age after which 37% Formaldehyde is no longer useful as a stock solution. Formaldehyde chemistry is moderately complex, but after discussions with other microscopists, m anufacturers and reviewing pertinent texts, the following observations are applicable. Formaldehyde should be stored at room temperature (cold temperatures encourage the formation of trioxymethylene with a resulting white precipitate) Formaldehyde should be stored tightly sealed, since expo sure to air encourages the oxidation of formaldehyde to formic acid (37% formaldehyde is usually shipped with 10 – 15% methanol to inhibit this change) . Our recommendation regarding 37% stock solutions: If a solution of 37% formaldehyde is clear, colorles s and has no precipitate, and has been stored at room temperature in a tightly sealed bottle that has not been exposed to sunlight, it should be good. However, we still do not recommend using a stock bottle that is older than 1 year. Bottles of 37% forma ldehyde that are already opened should not be used more than six months. Consequently, we recommend that labs purchase their formaldehyde more frequently and in smaller quantities than perhaps they have done in the past. Use of 37% Formaldehyde is not re commended for electron microscopy fixatives. A better choice is to use a higher grade, methanol – free formaldehyde , or a fresh solution made from paraformaldehyde (see further comments below) . Information about 10% Formalin The fixative 10% buffered form alin is commonly used to preserve tissues for routine histology in many labs. The formaldehyde has a greater chance for oxidation in this concentration of tissue fixative and eventually the solution will start to drop in pH, in spite of the buffer. We rec ommend that 10% buffered formalin solutions be used no longer than 3 months after they were initially mixed. The solution should be clear, colorless, with no precipitate and the pH should not be below 6.5. The other problem with 10% buffered formalin is the slowly increasing concentration of methanol (an unwanted byproduct of aging formaldehyde) . Methanol promotes clumping of proteins, instead of the cross – linking of proteins that formaldehyde performs. A methanol – free fixative will give the best prese rvation, particularly if you plan to use the tissue for antibody staining at a later time. The most common way to avoid methanol in a formaldehyde solution is to make the solution up fresh from crystalline paraformaldehyde. Paraformaldehyde can be quite hazardous to handle and it is often difficult to get it to go into solution. If your lab is not a regular user of formaldehyde fixatives, there are a couple of easier options that we recommend. One option is to purchase methanol – free formaldehyde (aq) in sealed ampoules. Simply add PBS to achieve the correct formaldehyde concentration and use immediately. Ten 10 ml ampoules of 16% methanol – free formaldehyde costs approximately $2 7 . (See sample protocol at the end of this document) The other option i s to buy 10% neutral buffered Formalin (4% formaldehyde) from a scientific supply house, use it for 3 – 6 months and then discard it (as a hazardous material) . There will be some methanol in this solution (typically 1 – 2%) , but if used soon after purchase thi s should not be significant for most users. The buffered solution helps slow the acidification process. A one liter bottle costs approximately $20 – 25. Store the fixative at room temperature. Local readers of this page should contact the CBA Histology Se rvice Lab (626 – 4415) if you have trouble locating a supplier. (Please note different suppliers use different buffering solutions. For consistent immunohistochemistry or immunofluorescence , users should stick with one supplier.)

Please note all content on this page was automatically generated via our AI-based algorithm. Please let us know if you find any errors.

Here is your PDF: Marketing Management 14th by Kotler and Keller; Keywords: Socioline.ru Files 5 283 Kotler Keller Marketing Management 14th

The number of pages within the document is: 812

The self-declared author(s) is/are:
Philip Kotler

The subject is as follows:
Original authors did not specify.

The original URL is: LINK

The access date was:
2019-02-09 15:44:08.388946

Please be aware that this may be under copyright restrictions. Please send an email to admin@pharmacoengineering.com for any AI-generated issues.

Loader Loading...
EAD Logo Taking too long?

Reload Reload document
| Open Open in new tab

The content is as follows:
Not able to be extracted

Please note all content on this page was automatically generated via our AI-based algorithm. Please let us know if you find any errors.

Here is your PDF: Concept Paper on revision of the points to consider on pharmacokinetics and pharmacodynamics in the development of antibacterial medicinal products (CHMP/EWP/2655/99) and conversion to a CHMP guideline; Keywords: 2014 february consultation 7 european +44 (0)20

The number of pages within the document is: 7

The self-declared author(s) is/are:
CHMP

The subject is as follows:
Original authors did not specify.

The original URL is: LINK

The access date was:
2019-02-02 23:23:24.462189

Please be aware that this may be under copyright restrictions. Please send an email to admin@pharmacoengineering.com for any AI-generated issues.

Loader Loading...
EAD Logo Taking too long?

Reload Reload document
| Open Open in new tab

The content is as follows:
7 Westferry Circus Canary Wharf London E14 4HB United Kingdom An agency of the European Union Telephone +44 (0)20 7418 8400 Facsimile +44 (0)20 7418 8416 E-mail info@ema.europa.eu Website www. ema.europa.eu © European Medicines Agency, 2014 . Reproduction is authorised provided the source is acknowledged. 20 February 2014 1 EMA/CHMP/792679/2013 2 Committee for Medicinal Products for Human Use (CHMP ) 3 Concept Paper on revision of the points to consider on 4 pharmacokinetics and pharmacodynamics in the 5 development of antibacterial medicinal products 6 (CHMP /EWP /2655/99) and conversion to a CHMP 7 guideline 8 9 Agreed by Infectious Diseases Worki ng Party November 2013 Adopted by CHMP for release for consultation 20 February 2014 Start of public consultation 28 February 2014 End of consultation (deadline for comments) 31 May 2014 10 The proposed guid eline will replace CPMP/EWP/2655/99 11 12 Comments s hould be provided using this template . The completed comments form should be sent t o IDWP secretariat @ema.europa.eu 13 Keywords Pharmacokinetics; pha rmacodynamics; exposure -response; target attainment 14 15

Please note all content on this page was automatically generated via our AI-based algorithm. Please let us know if you find any errors.

Here is your PDF: Clinical Pharmacology and Therapeutic Drug Monitoring of First-Line Anti-Tuberculosis Drugs; Keywords:

The number of pages within the document is: 9

The self-declared author(s) is/are:
Marieke G.G. Sturkenboom

The subject is as follows:
Original authors did not specify.

The original URL is: LINK

The access date was:
2019-02-02 23:22:43.898575

Please be aware that this may be under copyright restrictions. Please send an email to admin@pharmacoengineering.com for any AI-generated issues.

Loader Loading...
EAD Logo Taking too long?

Reload Reload document
| Open Open in new tab

The content is as follows:

Please note all content on this page was automatically generated via our AI-based algorithm. Please let us know if you find any errors.

Here is your PDF: Formaldehyde, Formalin, Paraformaldehyde Safe Work Practices; Keywords: formaldehyde exposure , – cause use used

The number of pages within the document is: 14

The self-declared author(s) is/are:
Ellen Gunderson

The subject is as follows:
Original authors did not specify.

The original URL is: LINK

The access date was:
2019-02-04 23:22:20.830656

Please be aware that this may be under copyright restrictions. Please send an email to admin@pharmacoengineering.com for any AI-generated issues.

Loader Loading...
EAD Logo Taking too long?

Reload Reload document
| Open Open in new tab

The content is as follows:
Page 1 of 14 Research and Occupational Safety January 2017 Formaldehyde, Formalin, Paraformaldehyde Safe Work Practices I. Introduction II. Formaldehyde Regulations, Exposure Limits and Air Monitoring III. Laboratory Planning and Preparation for Use IV. Engineering Controls V. Personal Protective Equipment (PPE ) VI. Formaldehyde Safe Use Practices VII. Forma l dehyde Spill Cleanup VIII. Acute Exposure IX. Formaldehyde Waste Collection , Disposal and Treatment Formaldehyde Template SOP Formaldehyde Online Training I. INTRODUCTION In its purest form, formaldehyde is a colorless, highly toxic and flammable gas with a strong pungent odor. However, it is most commonly used as an aqueous solution called formalin , which typically also contains some methanol as a stabilizer. Paraformalde hyde is a white crystalline powder of polymerized formaldehyde , a flammable solid that can emit formaldehyde gas when heated or mixed with water . Many laboratories at UW use formalin solutions and paraformaldehyde solutions or solids as part of their resea rch and clinical activities. It is commonly used in tissue fixing and preservation , and as an organic chemical reagent. The most widely used formaldehyde – containing chemical at UW is 10% neutral buffered (NB) formalin, which contains 4% formaldehyde. In 2011, the US Department of Health and Human Services named formaldehyde a known human carcinogen . Prolonged exposure to formaldehyde has been associated with cancers of the lung, nasopharynx, orpharynx and nasal passages (nose and throat) and some studi es suggest formaldehyde may cause leukemia, particularly myeloid leukemia , i n humans. It has also been associated with decreased fertility and adverse reproductive effects. Formaldehyde is a sensitizing agent that can cause an immune system response upon i nitial exposure. Subsequent exposure may cause severe allergic reactions of the skin, eyes and respiratory tract. Long – term or repeated exposure to low levels in the air or on the skin can cause as thma – like respiratory problems and skin irritation such as dermatitis and itching. Acute exposure can be highly irritating to the eyes, nose and throat. Because of the serious potential hazards for researchers and workers who may be exposed to formaldehyde as part of their work with formaldehyde – containing chemica ls, precautions must be taken to eliminate or reduce the potential for exposure as much as possible .

Please note all content on this page was automatically generated via our AI-based algorithm. Please let us know if you find any errors.

Here is your PDF: PHARMACOKINETICS, PHARMACODYNAMICS, AND DRUG DISPOSITION; Keywords:

The number of pages within the document is: 18

The self-declared author(s) is/are:
DAVID J. GREENBLATT

The subject is as follows:
Original authors did not specify.

The original URL is: LINK

The access date was:
2019-02-02 23:23:30.315664

Please be aware that this may be under copyright restrictions. Please send an email to admin@pharmacoengineering.com for any AI-generated issues.

Loader Loading...
EAD Logo Taking too long?

Reload Reload document
| Open Open in new tab

The content is as follows:
No readable content…

Please note all content on this page was automatically generated via our AI-based algorithm. Please let us know if you find any errors.

Here is your PDF: Bipolar Disorders and Lithium: Pharmacokinetics, Pharmacodynamics, Therapeutic Effects and Indications of Lithium: Review of Articles; Keywords:

The number of pages within the document is: 8

The self-declared author(s) is/are:
Original authors did not specify.

The subject is as follows:
Original authors did not specify.

The original URL is: LINK

The access date was:
2019-02-02 23:23:09.264676

Please be aware that this may be under copyright restrictions. Please send an email to admin@pharmacoengineering.com for any AI-generated issues.

Loader Loading...
EAD Logo Taking too long?

Reload Reload document
| Open Open in new tab

The content is as follows:
No readable content…

Please note all content on this page was automatically generated via our AI-based algorithm. Please let us know if you find any errors.

Here is your PDF: General Clinical Pharmacology Considerations for Pediatric Studies for Drugs and Biological Products ; Keywords: guidance federal register drug draft this document

The number of pages within the document is: 28

The self-declared author(s) is/are:
FDA/CDER/phanm

The subject is as follows:
Original authors did not specify.

The original URL is: LINK

The access date was:
2019-02-02 23:23:22.439393

Please be aware that this may be under copyright restrictions. Please send an email to admin@pharmacoengineering.com for any AI-generated issues.

Loader Loading...
EAD Logo Taking too long?

Reload Reload document
| Open Open in new tab

The content is as follows:
DRAFT GUIDANCE This guidance document is being distributed for comment purposes only. Federal Register Federal Register U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) December 2014 Clinical Pharmacology

Please note all content on this page was automatically generated via our AI-based algorithm. Please let us know if you find any errors.

Here is your PDF: COMPUTATIONAL CHEMISTRY; CHEMOINFORMATICS; COMPUTATIONAL MATERIALS SCIENCE; Keywords: computational materials data processing systems g06f this

The number of pages within the document is: 5

The self-declared author(s) is/are:
USPTO Editorial Division on behalf of EPO/USPTO

The subject is as follows:
Original authors did not specify.

The original URL is: LINK

The access date was:
2019-02-02 23:23:31.199591

Please be aware that this may be under copyright restrictions. Please send an email to admin@pharmacoengineering.com for any AI-generated issues.

Loader Loading...
EAD Logo Taking too long?

Reload Reload document
| Open Open in new tab

The content is as follows:
CPC – G16C – 2019.02 G16C COMPUTATIONAL CHEMISTRY; CHEMOINFORMATICS; COMPUTATIONAL MATERIALS SCIENCE Definition statement This place covers: Data processing methods or systems for the storage, retrieval, analysis, distribution or visualisation of physicochemical or structural data of chemical particles, elements, compounds, or mixtures. Computational theoretical chemistry and computational materials science. Data processing methods or systems for investigating physics or chemistry of new or existing materials or phenomena associated with their design, synthesis, processing, characterization, or utilisation. This group also covers computational chemistry and computational materials science methods or systems where the digital data processing is inherent or implicit, although not explicitly mentioned. Relationships with other classification places This subclass covers computational chemistry, which comprises computational theoretical chemistry, chemoinformatics, and computational materials science, whereas subclass G16B covers bioinformatics. In order to determine whether classification should be directed to this subclass or to subclass G16B , one has to take into account the type of molecule(s), whose characterising features are processed by a computational algorithm. Following the definition statements of computational chemistry, computational materials science and bioinformatics, processing of data related to chemical entities (i.e. chemical particles, elements, compounds, mixtures) and/or materials should be classified under G16C . Processing of data related to nucleic acids, proteins, peptides and/or amino acids should be classified under G16B . References Informative references Attention is drawn to the following places, which may be of interest for search: Investigating or analysing materials by determining their chemical or physical properties G01N Chromatographic signal analysis G01N 30/86 Systems controlled by a computer G05B 15/00 Computer input/output arrangements G06F 3/00 Computer architectures or program control G06F 9/00 Information retrieval; Database structures therefor; File system structures therefor G06F 16/00 Complex mathematical operations G06F 17/10 Computer-aided design G06F 17/50 Pattern recognition G06K 9/00 Computer systems using neural network models G06N 3/02 1

Please note all content on this page was automatically generated via our AI-based algorithm. Please let us know if you find any errors.

Here is your PDF: Continuous Home Monitoring Of Glucose | Diabetes Care; Keywords: continuoushomemonitoringofglucose improvedglycemiccontrolwithreal-lifeuseofcontinuousglucosesensors inadultsubjectswithtype1diabetes satishk.g arg,md1,2,3williamc.k elly,bs1maryk.v oelmle,ms,fnp,cde

The number of pages within the document is: 3

The self-declared author(s) is/are:
Satish K. Garg, MD

The subject is as follows:
Original authors did not specify.

The original URL is: LINK

The access date was:
2019-01-30 22:53:46.460956

Please be aware that this may be under copyright restrictions. Please send an email to admin@pharmacoengineering.com for any AI-generated issues.

Loader Loading...
EAD Logo Taking too long?

Reload Reload document
| Open Open in new tab

The content is as follows:
No readable content…

Please note all content on this page was automatically generated via our AI-based algorithm. Please let us know if you find any errors.